King's College London

Research portal

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life

Research output: Contribution to journalArticle

M A Richards, P Hopwood, A J Ramirez, C J Twelves, J Ferguson, W M Gregory, R Swindell, W Scrivener, J Miller, A Howell, R.D. Rubens

Original languageEnglish
Pages (from-to)1023-8
Number of pages6
JournalEuropean Journal of Cancer
Issue number6-7
Publication statusPublished - 1992

King's Authors


The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454